Sugi Predict

Sugi Predict / Compounds / SCHEMBL6435819

SCHEMBL6435819

SCHEMBL6435819

CC(C)[C@H](NC(=O)c1ccc2c(Cl)cnc(Cl)c2c1)C(=O)OC(C)(C)C

nearest known ligand 0.43

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
▸ TAS1R3 Q7RTX0 2/20 0.43
▸ TAS1R1 Q7RTX1 2/20 0.43
▸ CA1 P00915 3/20 0.41
▸ CA2 P00918 3/20 0.41
▸ TRPA1 O75762 2/20 0.40
▸ MAPK3 P27361 1/20 0.37
▸ MAPK1 P28482 1/20 0.37
▸ NPR3 P17342 1/20 0.37
▸ LMNA P02545 1/20 0.35
▸ RAB9A P51151 1/20 0.35
▸ SMN1; SMN2 Q16637 1/20 0.35
▸ PLG P00747 2/20 0.35
▸ PLAU P00749 2/20 0.35
▸ PLAT P00750 1/20 0.35
▸ LRRK2 Q5S007 1/20 0.35
▸ MRGPRX4 Q96LA9 1/20 0.35
▸ NPSR1 Q6W5P4 1/20 0.35
▸ DGAT2 Q96PD7 2/20 0.35
▸ GPR132 Q9UNW8 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6435824 1.00 TAS1R3 (0.43) TAS1R3TAS1R1CA1CA2TRPA1
SCHEMBL6437307 0.89 MAPT (0.43) CA1CA2MAPK3MAPK1NPSR1
SCHEMBL6432919 0.85 CA1 (0.39) TAS1R3TAS1R1CA1CA2TRPA1
SCHEMBL6434625 0.85 NPSR1 (0.48) TAS1R3TAS1R1CA1CA2MAPK1
SCHEMBL6434626 0.85 NPSR1 (0.48) TAS1R3TAS1R1CA1CA2MAPK1
SCHEMBL6433807 0.82 GRN (0.46) TAS1R3TAS1R1CA1CA2MAPK3
SCHEMBL6437559 0.82 ROCK2 (0.38) TAS1R3TAS1R1CA1CA2NPSR1
SCHEMBL6433809 0.82 GRN (0.46) TAS1R3TAS1R1CA1CA2MAPK3
SCHEMBL6437004 0.81 NPR3 (0.41) TAS1R3TAS1R1NPR3LMNASMN1; SMN2
SCHEMBL6437001 0.81 NPR3 (0.41) TAS1R3TAS1R1NPR3LMNASMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20050026836-A1 Composition for the treatment of damaged tissue DACK KEVIN NEIL (GB) 2005-02-03 — — US disclosed
US-20030199440-A1 Composition for the treatment of damaged tissue PFIZER INC. 2003-10-23 — — US disclosed
EP-1077945-B1 ISOQUINOLINES AS UROKINASE INHIBITORS PFIZER (US) 2003-01-08 — — EP disclosed
EP-1242120-A2 COMBINATIONS OF GROWTH FACTORS AND I:UPA OR I:MMP FOR THE TREATMENT OF DAMAGED TISSUE Pfizer Limited (GB) 2002-09-25 — — EP disclosed
WO-2001049309-A2 COMBINATIONS OF GROWTH FACTORS AND I: UPA OR I: MMP FOR THE TREATMENT OF DAMAGED TISSUE PFIZER LIMITED (GB) 2001-07-12 — — WO disclosed
EP-1077945-A1 ISOQUINOLINES AS UROKINASE INHIBITORS PFIZER INC. (US) 2001-02-28 — — EP disclosed
US-6093731-A Isoquinolines PFIZER INC. 2000-07-25 — — US disclosed
WO-2000005214-A2 ISOQUINOLINES AS UROKINASE INHIBITORS PFIZER INC. (US) 2000-02-03 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030199440-A1 Composition for the treatment of damaged tissue MMP1, SERPINE1, COL14A1 TAS1R3 3747/4885TAS1R1 3148/4885CA1 3943/4885
US-20050026836-A1 Composition for the treatment of damaged tissue MMP1, SERPINE1, COL14A1 TAS1R3 3747/4885TAS1R1 3148/4885CA1 3943/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.